Welcome to our dedicated page for ASLAN Pharmaceuticals American Depositary Shares news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals American Depositary Shares stock.
ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments that transform the lives of patients. Headquartered in Singapore with offices in Taiwan and China, ASLAN is tackling high-prevalence diseases in Asia and orphan indications in the United States and Europe.
ASLAN's strategic portfolio includes four product candidates targeting validated growth pathways, novel immune checkpoints, and cancer metabolic pathways. Their flagship projects are eblasakimab, a first-in-class antibody targeting the IL-13 receptor for moderate-to-severe atopic dermatitis (AD), and farudodstat, an oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for alopecia areata (AA).
In recent developments, eblasakimab has shown promising results in a Phase 2b, dose-ranging study, achieving significant improvements in AD patients. Concurrently, farudodstat is progressing through a Phase 2a, proof-of-concept trial with interim results expected soon.
ASLAN actively collaborates with industry leaders such as Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to bolster their research and development efforts. The company's strategic alliances aim to leverage combined expertise for enhanced therapeutic outcomes.
On March 12, 2024, ASLAN announced a definitive agreement to sell 5,000,000 American Depositary Shares (ADSs) at $1.00 per ADS in a direct offering, with warrants issued in a concurrent private placement. The proceeds will fund ongoing R&D activities and general corporate purposes.
Despite financial challenges, including a reported deficit of $13.3 million in stockholders’ equity for 2023, ASLAN is committed to regaining compliance with Nasdaq listing requirements. This determination is underscored by their continuous efforts to advance their clinical pipeline and explore new research collaborations, such as their recent agreement with Zenyaku Kogyo Co., Ltd.
ASLAN's proactive approach, supported by a solid management team with deep global and regional expertise, aims to generate significant clinical advances and commercial opportunities. For more information, visit the ASLAN website or follow them on LinkedIn.
ASLAN Pharmaceuticals (NASDAQ: ASLN) announced acceptance of two late-breaking abstracts for the 1st International Societies for Investigative Dermatology (ISID) Meeting in Tokyo from May 10-13, 2023. One abstract focuses on eblasakimab and its effects in atopic dermatitis (AD), while the other highlights farudodstat in alopecia areata. Published data show that eblasakimab significantly improves Eczema Area and Severity Index (EASI) scores, particularly in sensitive areas. The treatment also inhibits neuronal sensitization to itch, potentially offering broad therapeutic benefits. Results from the Phase 2 TREK-AD study are expected in early July 2023, while an upcoming proof-of-concept trial for farudodstat is planned for Q2 2023.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced that it has regained compliance with Nasdaq's minimum bid price requirement, with a closing bid price above $1.00 for 10 consecutive business days, as of March 27, 2023. This follows a previous notice from Nasdaq on March 28, 2022, regarding non-compliance due to the bid price dropping below $1.00. The company develops innovative treatments, including eblasakimab for atopic dermatitis and farudodstat for alopecia areata, with ongoing clinical trials. ASLN's continued listing on Nasdaq is contingent upon meeting all applicable standards moving forward.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced its financial results for Q4 and full year 2022, reporting a net loss of $51.4 million compared to $31.3 million in 2021. The increase in loss is primarily due to elevated research and development expenses of $38.0 million, driven by clinical development costs for eblasakimab. The company has successfully enrolled patients in its TREK-AD Phase 2b trial and expects topline data by early July 2023. Following a recent $20 million financing, ASLAN anticipates its cash runway extended through Q2 2024. Additionally, a Phase 2 trial for farudodstat in alopecia areata is set to begin in Q2 2023, with data expected in Q1 2024.
FAQ
What is the current stock price of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is the market cap of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is ASLAN Pharmaceuticals' focus?
What are ASLAN Pharmaceuticals' main products?
Where is ASLAN Pharmaceuticals headquartered?
Who are ASLAN Pharmaceuticals’ partners?
What recent financial activities has ASLAN Pharmaceuticals undertaken?
What clinical advancements has ASLAN Pharmaceuticals made recently?
How is ASLAN Pharmaceuticals addressing its financial challenges?
What is the purpose of ASLAN Pharmaceuticals’ recent collaboration with Zenyaku Kogyo?
What is eblasakimab?
What are the potential benefits of farudodstat?
